Valeant (VRX) Shares Rise Following FY12 Outlook
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Income from operations: 72.17M
Today's EPS Names:
ECHO, ABTC, DEA, More
Financial Fact:
Income from operations: 72.17M
Today's EPS Names:
ECHO, ABTC, DEA, More
Join SI Premium – FREE
Shares of Valeant Pharma (NYSE: VRX) have just turned positive following an 8-K filing which offers some insight into FY12 results.
Valeant expecting FY12 sales of $3.1-$3.4 billion and cash EPS of $3.95-$4.20. The company expects adjusted cash flow from operations to be greater than $1.2 billion.
Valeant expecting FY12 sales of $3.1-$3.4 billion and cash EPS of $3.95-$4.20. The company expects adjusted cash flow from operations to be greater than $1.2 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sportradar Group AG (SRAD) Misses Q2 EPS by 6c, Offers Guidance
- X-energy and SGL Carbon agree to double nuclear graphite output by 2030
- Eaton (ETN) Tops Q2 EPS by 8c, Beats on Revenue; Offers Q3 Guidance
Create E-mail Alert Related Categories
Guidance, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
